These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 27690683)

  • 61. [Surveillance of cytomegalovirus for antiviral efficacy and risk factors in allogeneic hematopoietic stem cell transplantation].
    Jia JS; Liu DP; Huang XJ; Wu T; Liu DH; Zhang YC; Su H; Wang JB; Zhou JR; Liu Q; Ying MY; Sun RJ; Duan X; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):749-54. PubMed ID: 16928314
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation].
    Xu Z; Huang X; Sun Y; Wang F; Yan C; Zhang X; Han W; Chen Y; Wang J; Chen H; Wang Y; Zhang Y; Liu K; Xu L
    Zhonghua Nei Ke Za Zhi; 2015 Feb; 54(2):101-5. PubMed ID: 25907838
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Cytomegalovirus infections following allogeneic hematopoietic stem cell transplantation: prophylaxis and treatment].
    Katayama Y; Iwato K
    Rinsho Ketsueki; 2019; 60(6):635-645. PubMed ID: 31281156
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients.
    Razonable RR
    Am J Health Syst Pharm; 2005 Apr; 62(8 Suppl 1):S7-13. PubMed ID: 15821266
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.
    Ariza-Heredia EJ; Nesher L; Chemaly RF
    Cancer Lett; 2014 Jan; 342(1):1-8. PubMed ID: 24041869
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Quantitative real-time PCR--usefulness in detection and monitoring of CMV infection after hematopeietic stem cells transplant].
    Grabarczyk P; Brojer E; Nasiłowska B; Mariańska B
    Pol Merkur Lekarski; 2006 Sep; 21(123):227-31. PubMed ID: 17163182
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
    Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
    La Rosa C; Wang Z; Lacey SF; Lalimarmo MM; Krishnan A; Longmate J; Diamond DJ
    Exp Hematol; 2006 Apr; 34(4):497-507. PubMed ID: 16569596
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
    Nakamura R; Battiwalla M; Solomon S; Follmann D; Chakrabarti S; Cortez K; Hensel N; Childs R; Barrett AJ
    Biol Blood Marrow Transplant; 2004 Jan; 10(1):49-57. PubMed ID: 14752779
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation.
    Cui J; Zhao K; Sun Y; Wen R; Zhang X; Li X; Long B
    Front Immunol; 2022; 13():971156. PubMed ID: 36211358
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
    El Chaer F; Mori N; Shah D; Oliver N; Wang E; Jan A; Doan V; Tverdek F; Tayar J; Ariza-Heredia E; Chemaly RF
    Antiviral Res; 2016 Nov; 135():91-96. PubMed ID: 27594527
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients].
    Silva F; Martins A; Ferraz P; Lopes D; Bastos J; Joana Araújo JA; Trigo F; Pinto R; Silva-Pinto A
    Acta Med Port; 2024 Oct; 37(10):733-740. PubMed ID: 39008637
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cytomegalovirus in hematopoietic stem cell transplant recipients.
    Ljungman P; Hakki M; Boeckh M
    Infect Dis Clin North Am; 2010 Jun; 24(2):319-37. PubMed ID: 20466273
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Surveillance of CMV infection in allo-HSCT recipients and guidance on preemptive therapy by RQ-PCR.
    Li Y; Gao L; Wang LL; Ding Y; Xu YY; Li HH; Jing Y; Bo J; Huang WR; Wang QS; Gao CJ; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):161-8. PubMed ID: 23484712
    [TBL] [Abstract][Full Text] [Related]  

  • 79. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.
    de la Torre-Cisneros J; Fariñas MC; Castón JJ; Aguado JM; Cantisán S; Carratalá J; Cervera C; Cisneros JM; Cordero E; Crespo-Leiro MG; Fortún J; Frauca E; Gavaldá J; Gil-Vernet S; Gurguí M; Len O; Lumbreras C; Marcos MÁ; Martín-Dávila P; Monforte V; Montejo M; Moreno A; Muñoz P; Navarro D; Pahissa A; Pérez JL; Rodriguez-Bernot A; Rumbao J; San Juan R; Santos F; Varo E; Zurbano F;
    Enferm Infecc Microbiol Clin; 2011 Dec; 29(10):735-58. PubMed ID: 21925772
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
    Thiele T; Krüger W; Zimmermann K; Ittermann T; Wessel A; Steinmetz I; Dölken G; Greinacher A
    Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.